Cancer Treatment Centers of America

Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients

CHICAGO, June 15, 2009-Body mass index (BMI) should be taken into account when assessing a cancer patient’s vitamin D status, according to researchers at Cancer Treatment Centers of America (CTCA), who found that obese cancer patients had significantly lower levels of vitamin D compared to non-obese patients.

The association between vitamin D and obesity remains unsettled with studies reporting conflicting findings on the relationship between the two. This association assumes even greater importance in cancer because of the alleged role of vitamin D in cancer.

"Currently, the dietary recommendations for vitamin D do not take into account a patient’s BMI," said Carolyn Lammersfeld, national director of nutrition for CTCA and a principal investigator in the study. "We investigated the relationship between vitamin D and BMI in a large sample of cancer patients and found that as BMI groups increased from normal to overweight or obese classifications, there was a significant decrease in vitamin D."

The researchers evaluated a group of 740 cancer patients seen at CTCA from January 2008 to June 2008. Of the 740 patients, 303 were male and 437 female, with a mean age at presentation of 55.7 years (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vitamin D (serum 25(OH)D) was 21.9 ng/ml (SD = 13.5).

The study concluded that obese cancer patients (BMI >=30 kg/m2) had significantly lower levels of vitamin D compared to non-obese patients (BMI <30 kg/m2). BMI should be taken into account when assessing a patient’s vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients, researchers determined.

This study was presented at the American Society of Clinical Oncology (ASCO) annual meeting, May 29-June 2, 2009, and was publicly released on ASCO’s Web site, www.asco.org, on May 14, 2009.

About Cancer Treatment Centers of America®
Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Reflecting our patient-centered approach to cancer care, our patient satisfaction scores consistently rank among the highest in the country for cancer care providers, and CTCA is also rated one of the most admired hospital systems in the country in national consumer surveys. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.